Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

22.43USD
23 Jan 2018
Change (% chg)

$0.14 (+0.63%)
Prev Close
$22.29
Open
$22.43
Day's High
$22.81
Day's Low
$22.23
Volume
127,213
Avg. Vol
214,158
52-wk High
$49.21
52-wk Low
$19.73

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 4.21
Market Cap(Mil.): $1,122.56
Shares Outstanding(Mil.): 28.90
Dividend: --
Yield (%): --

Financials

BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

3:18am IST

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

08 Jan 2018

BRIEF-Five Prime Therapeutics Submits Investigational New Drug Application For FPA150

* FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150

04 Jan 2018

BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement

* FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION

20 Dec 2017

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

09 Nov 2017

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

07 Nov 2017

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

24 Oct 2017

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

30 Aug 2017

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* ‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​

29 Aug 2017

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

09 Aug 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥3,514 +50.00
Novartis AG (NOVN.S) CHF83.60 --
AstraZeneca plc (AZN.L) 5,101.00 +47.00
Eli Lilly and Co (LLY.N) $84.42 -1.02
ArQule, Inc. (ARQL.OQ) $1.70 -0.06

Earnings vs. Estimates